{"entity":{"id":"idea-fund-academic-adc-bispecific-platform","kind":"idea","name":"An open engineering platform for academic ADCs and bispecifics","aka":[],"tldr":"Academic labs find new tumour targets but cannot turn an antibody into an antibody-drug conjugate or a bispecific without licensed linker and payload technology. A shared platform would provide that at no cost for first trials.","summary":"A publicly-funded platform holding licences (or developing its own patent-free versions) for linker-payload chemistries, site-specific conjugation, bispecific formats and CAR constructs, offered royalty-free to academic teams for research and first-in-human studies, with commercial terms triggered only on licensing to a company. Paired with GMP manufacturing at translational institutes, this lets academic centres test conjugates against novel or rare-cancer antigens that no company will prioritise. The Structural Genomics Consortium's open chemical probes and the IAVI/Neutralizing Antibody Center model for HIV antibodies are precedents for open engineering infrastructure.","asOf":"2026-09-08","links":[{"label":"Structural Genomics Consortium","url":"https://www.thesgc.org/"}],"tags":[],"related":["idea-fund-translational-institutes-gmp","idea-fund-shared-personalised-therapy-gmp"],"cancers":[],"sections":[],"technologies":["adc","bispecific-antibody","site-specific-conjugation","t-cell-engager"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-translational-valley","b-ip-collaboration"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"An open ADC and bispecific platform enables at least ten academic first-in-human trials of conjugates against novel or rare-cancer antigens within five years, compared with near zero today, and at least two are subsequently licensed.","rationale":"Modern ADC success is largely payload and linker engineering, which is patent-encumbered and inaccessible to academics; the antigens most likely to matter for rare cancers are found in academia. Open tool infrastructure has repeatedly seeded new fields (SGC probes, Addgene plasmids).","test":"Fund the platform for three years, count academic conjugate programmes reaching GMP manufacturing and first-in-human dosing, and compare with the prior five-year baseline.","maturity":"speculative","actor":"engineering","cost":"medium","horizonYears":4},"route":"/ideas/idea-fund-academic-adc-bispecific-platform/","neighbours":{"idea":[{"id":"idea-fund-translational-institutes-gmp","kind":"idea","name":"Regional translational institutes with academic GMP suites and IND teams","route":"/ideas/idea-fund-translational-institutes-gmp/"},{"id":"idea-fund-shared-personalised-therapy-gmp","kind":"idea","name":"Shared modular GMP facilities for academic personalised vaccines and cell products","route":"/ideas/idea-fund-shared-personalised-therapy-gmp/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"site-specific-conjugation","kind":"technology","name":"Site-specific conjugation & linker chemistry","route":"/technologies/site-specific-conjugation/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"bottleneck":[{"id":"b-ip-collaboration","kind":"bottleneck","name":"Secrecy and intellectual property block collaboration","route":"/bottlenecks/b-ip-collaboration/"},{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/"}]}}